Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ: PTGX )

39.22 -0.08 (-0.20%)
Streaming Delayed Price Updated: 1:04 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 151,730
Open 38.98
Bid (Size) 39.18 (1)
Ask (Size) 39.25 (5)
Prev. Close 39.30
Today's Range 38.84 - 39.55
52wk Range 21.43 - 48.89
Shares Outstanding 59,598,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Via ACCESSWIRE
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Via ACCESSWIRE

Performance

YTD
+67.46%
+67.46%
1 Month
-13.86%
-13.86%
3 Month
-15.00%
-15.00%
6 Month
+23.49%
+23.49%
1 Year
+70.37%
+70.37%

More News

Read More
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Via Benzinga
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Via ACCESSWIRE
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Via ACCESSWIRE
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Via ACCESSWIRE
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Via ACCESSWIRE
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Via Benzinga
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Via ACCESSWIRE
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Via ACCESSWIRE
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Via ACCESSWIRE
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Via Benzinga
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Via ACCESSWIRE
3 Growth Stocks No One Is Watching (But They Should Be)
Via InvestorPlace
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Via ACCESSWIRE
The 3 Best Biotech Stocks to Buy in June 2024
Via InvestorPlace
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.